Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Schjesvold, Roman Hájek, Philippe Moreau, Felipe de Arriba de la Fuente, María Victoria Mateos, Sharon West, Andrew Spencer, S. Vincent Rajkumar, Kaveri Suryanarayan, Michael Czorniak, Cong Li, Zhaoyang Teng, Richard Labotka, Meletios A. Dimopoulos

Research output: Contribution to journalComment/debatepeer-review

Abstract

Low-resolution figures were inadvertently created during production and published.

Original languageEnglish (US)
JournalAnnals of hematology
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)'. Together they form a unique fingerprint.

Cite this